Eric Piver1,2, Audrey Boyer1,3, Julien Gaillard4, Anne Bull1, Elodie Beaumont1, Philippe Roingeard1,4, Jean-Christophe Meunier1. 1. INSERM U966, Faculté de Médecine, Université François Rabelais and CHRU de Tours, Tours, France. 2. Biochimie & Biologie Moléculaire, Hôpital Trousseau, CHRU de Tours, Tours, France. 3. Liang Laboratory, Liver Diseases Branch, NIDDK, National Institutes of Health, Bethesda, Maryland, USA. 4. Plate-Forme IBiSA des Microscopies, PPF ASB, Université François Rabelais and CHRU de Tours, Tours, France.
Abstract
OBJECTIVE: HCV particles are associated with very low-density lipoprotein components in chronically infected patients. These hybrid particles, or 'lipo-viro particles' (LVPs), are rich in triglycerides, and contain the viral RNA, the capsid protein, E1E2 envelope glycoproteins and apolipoproteins B and E. However, their specific ultrastructural organisation has yet to be determined. We developed a strategy for the preparation of any viral sample that preserves the native structure of the LVPs, facilitating their precise morphological characterisation. DESIGN: Using a strategy based on the direct specific immunocapture of particles on transmission electron microscopy (TEM) grids, we characterised the precise morphology of the viral particle by TEM. RESULTS: The LVP consists of a broad nucleocapsid surrounding an electron-dense centre, presumably containing the HCV genome. The nucleocapsid is surrounded by an irregular, detergent-sensitive crescent probably composed of lipids. Lipid content may determine particle size. These particles carry HCV E1E2, ApoB and ApoE, as shown in our immuno-EM analysis. Our results also suggest that these putative LVPs circulate in the serum of patients as part of a mixed population, including lipoprotein-like particles and complete viral particles. CONCLUSIONS: Twenty-five years after the discovery of HCV, this study finally provides information about the precise morphological organisation of viral particles. It is truly remarkable that our TEM images fully confirm the ultrastructure of LVPs predicted by several authors, almost exclusively from the results of molecular biology studies. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
OBJECTIVE: HCV particles are associated with very low-density lipoprotein components in chronically infectedpatients. These hybrid particles, or 'lipo-viro particles' (LVPs), are rich in triglycerides, and contain the viral RNA, the capsid protein, E1E2 envelope glycoproteins and apolipoproteins B and E. However, their specific ultrastructural organisation has yet to be determined. We developed a strategy for the preparation of any viral sample that preserves the native structure of the LVPs, facilitating their precise morphological characterisation. DESIGN: Using a strategy based on the direct specific immunocapture of particles on transmission electron microscopy (TEM) grids, we characterised the precise morphology of the viral particle by TEM. RESULTS: The LVP consists of a broad nucleocapsid surrounding an electron-dense centre, presumably containing the HCV genome. The nucleocapsid is surrounded by an irregular, detergent-sensitive crescent probably composed of lipids. Lipid content may determine particle size. These particles carry HCV E1E2, ApoB and ApoE, as shown in our immuno-EM analysis. Our results also suggest that these putative LVPs circulate in the serum of patients as part of a mixed population, including lipoprotein-like particles and complete viral particles. CONCLUSIONS: Twenty-five years after the discovery of HCV, this study finally provides information about the precise morphological organisation of viral particles. It is truly remarkable that our TEM images fully confirm the ultrastructure of LVPs predicted by several authors, almost exclusively from the results of molecular biology studies. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
Authors: Holly Freedman; Michael R Logan; Darren Hockman; Julia Koehler Leman; John Lok Man Law; Michael Houghton Journal: J Virol Date: 2017-03-29 Impact factor: 5.103
Authors: Katharina Herzog; Simonetta Bandiera; Sophie Pernot; Catherine Fauvelle; Frank Jühling; Amélie Weiss; Anne Bull; Sarah C Durand; Béatrice Chane-Woon-Ming; Sébastien Pfeffer; Marion Mercey; Hervé Lerat; Jean-Christophe Meunier; Wolfgang Raffelsberger; Laurent Brino; Thomas F Baumert; Mirjam B Zeisel Journal: Gut Date: 2019-05-10 Impact factor: 31.793
Authors: Ursula Andreo; Ype P de Jong; Margaret A Scull; Jing W Xiao; Koen Vercauteren; Corrine Quirk; Michiel C Mommersteeg; Sonia Bergaya; Arjun Menon; Edward A Fisher; Charles M Rice Journal: Cell Mol Gastroenterol Hepatol Date: 2017-07-19